Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012;33(1):40-7.
doi: 10.1080/08897077.2011.620475.

Buprenorphine-naloxone maintenance following release from jail

Joshua D Lee  1 , Ellie Grossman, Andrea Truncali, John Rotrosen, Andrew Rosenblum, Stephen Magura, Marc N Gourevitch
Affiliations
Comparative Study

Buprenorphine-naloxone maintenance following release from jail

Joshua D Lee et al. Subst Abus. 2012.

Abstract

Primary care is understudied as a reentry drug and alcohol treatment setting. This study compared treatment retention and opioid misuse among opioid-dependent adults seeking buprenorphine/naloxone maintenance in an urban primary care clinic following release from jail versus community referrals. Postrelease patients were either (a) induced to buprenorphine in-jail as part of a clinical trial, or (b) seeking buprenorphine induction post release. From 2007 to 2008, N = 142 patients were new to primary care buprenorphine: n = 32 postrelease; n = 110 induced after community referral and without recent incarceration. Jail-released patients were more likely African American or Hispanic and uninsured. Treatment retention rates for postrelease (37%) versus community (30%) referrals were similar at 48 weeks. Rates of opioid positive urines and self-reported opioid misuse were also similar between groups. Postrelease patients in primary care buprenorphine treatment had equal treatment retention and rates of opioid abstinence versus community-referred patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare they have no conflict of interests. Drs. Lee and Gourevitch receive extramural grants from Cephalon and Alkermes Inc. supporting studies of alcohol treatment.

Figures

Figure 1
Figure 1
Treatment Retention: Jail- vs. Community-Referrals to Primary Care Buprenorphine Treatment *Treatment retention was measured as the period from the baseline visit though the last week of the last active buprenorphine prescription.
Figure 2
Figure 2
a–b. Rates of urine toxicologies positive for illicit methadone or opiates and self-reported illicit opioid use: group means through week 24 2a. Urine toxicology results display the proportions (group means) of individuals with any urines positive for opioids among during the corresponding 4-week intervals. Baseline results represents initial urine toxicology results in primary care buprenorphine treatment for all participants (community referrals and post-release jail referrals). 2b. Opioid use data indicate the proportions (group means) of patients reporting any illicit or non-prescribed opioid use during the corresponding 4-week intervals. Baseline results represent current use (last 7 days) at the initial primary care buprenorphine visit among community referrals, or pre-arrest use among jail referrals. *Error bars represent 95% confidence intervals for group mean estimates.
See this image and copyright information in PMC

References

    1. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: A Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004. - PubMed
    1. Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27(2):153–159. - PubMed
    1. Reynaud-Maurupt C, Caer Y, Escaffre N, Gagneau M, Galinier A, Marzo JN, Meroueh F. High-dose buprenorphine substitution during incarceration. Presse Med. 2005;34:487–490. - PubMed
    1. Garcia CA, Correa GC, Viver AD, et al. Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J. Addict. Med. 2007;(1):126–132. - PubMed
    1. Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99(1–3):222–230. - PMC - PubMed

Publication types